Where Will LAVA Therapeutics NV (LVTX) Stock Go Next After It Has Gained 24.79% in a Week?

LAVA Therapeutics NV (LVTX) stock is up 24.79% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

LAVA Therapeutics NV has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LVTX!

See Full LVTX Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With LVTX Stock Today?

LAVA Therapeutics NV (LVTX) stock has gained 3.93% while the S&P 500 is lower by -0.15% as of 11:15 AM on Monday, Nov 13. LVTX is up $0.06 from the previous closing price of $1.40 on volume of 31,468 shares. Over the past year the S&P 500 is up 11.40% while LVTX is lower by -72.19%. LVTX lost -$1.55 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for LAVA Therapeutics NV click here.

More About LAVA Therapeutics NV

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells. Click Here to get the full Stock Report for LAVA Therapeutics NV stock.